Good afternoon :)
$
₹
Zoetis Inc

Zoetis Inc

ZTS

NYSE
Asset Logo

Zoetis Inc

ZTS

NYSE
$78.791.27% (+0.99)
$
₹
$78.791.27% (+0.99)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Large Cap

With a market cap of $32.3B the stock is ranked 461

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

12.86
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

10.62
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$6.08
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

15.06
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

27.69%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.54%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 17 analysts reports

Buy
6 analysts
Hold
11 analysts
Sell
0 analyst

Price Upside

+12.46%

Earnings Growth

-3.19%

Rev. Growth

-2.28%

See Detailed Forecast

Company Profile

Company Profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.94
42.94
1Y Return
69.1%
69.1%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.77
40.77
1Y Return
48.41%
48.41%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
112.55
112.55
1Y Return
69.01%
69.01%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
29.93
29.93
1Y Return
32.26%
32.26%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.42
25.42
1Y Return
3.56%
3.56%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 12.46% growth, versus a trailing 3-year CAGR of -19.85%.

2026
Current$78.8Baseline
Analyst Target - 1 year
Target$88.62+12.46%

All values in $

202220232024202520262027$106.23$141.53$176.84Target+12.46%
2026
Current$78.8Baseline
Analyst Target - 1 year
Target$88.62+12.46%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -2.28% growth, versus a trailing 3-year CAGR of 5.42%.

2025
Current$9.46Baseline
Forecast for Dec 2026
High$9.37-0.97%
Average$9.25-2.28%
Low$9.09-3.89%

All values in $ Billion

2021202220232024202520267.778.088.549.259.46Low-3.89%Average-2.28%High-0.97%
2025
Current$9.46Baseline
Forecast for Dec 2026
High$9.37-0.97%
Average$9.25-2.28%
Low$9.09-3.89%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -3.19% growth, versus a trailing 3-year CAGR of 9.57%.

2025
Current$6.42Baseline
Forecast for Dec 2026
High$6.27-2.34%
Average$6.21-3.19%
Low$6.17-3.83%

All values in $

2021202220232024202520264.74.885.325.926.42Low-3.83%Average-3.19%High-2.34%
2025
Current$6.42Baseline
Forecast for Dec 2026
High$6.27-2.34%
Average$6.21-3.19%
Low$6.17-3.83%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.4
0.7
2.3
0.6
2.2
0.6
2.4
0.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue2.192.362.382.312.222.462.42.382.262.46
Net Income0.590.620.680.580.630.710.720.600.600.69
Net Profit Margin27.35%26.42%28.55%25.07%28.42%29.18%30.04%25.26%26.56%27.99%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Zoetis Inc 12.8610.6215.06
Eli Lilly and Company42.9433.651.22
Johnson & Johnson40.777.862.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ZTS with any stock or ETF
Compare ZTS with any stock or ETF
Comparing from
ZTS
LLY
JNJ
Loading...

Frequently asked questions

  1. Zoetis Inc (ZTS) share price today is $78.79 as of October 30, 2026 at 1:30 AM IST. The stock touched a day high of $79.18 and a day low of $77.75.

  2. Zoetis Inc stock trades on NYSE under the ticker symbol ZTS.

  3. Zoetis Inc's market capitalization is $32.32B as of October 30, 2026 at 1:30 AM IST.

  4. Zoetis Inc's price-to-earnings (P/E) ratio is 12.86 as of October 29, 2026.

  5. Zoetis Inc's price-to-book (P/B) ratio is 10.62 as of October 29, 2026.

  6. Yes, Zoetis Inc pays a dividend, with a current dividend yield of 2.54%.

  7. Yes, You can buy Zoetis Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Zoetis Inc shares in three steps: 1. Search Zoetis Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Zoetis Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Zoetis Inc (ZTS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1269 shares at the current price of $78.79.

Loading...